

WISCONSIN MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
August 11, 2010

In Attendance:

	Committee Member	Present--Yes or No
1	Rosanne Barber	Yes
2	Catherine Decker, PharmD	Yes
3	Bradley Fedderly, M.D.	No
4	Lawrence Fleming, M.D.	Present until 2:30 pm
5	Al Liegel, RPh	Yes
6	Kevin Izard, M.D.	Yes
7	Steve Maike, RPh	Yes
8	Pat Towers	Yes
9	Alicia Walker, PharmD	Yes
10	Michael Witkovsky, M.D.	No
11	James Boblin, M.D.	Yes
12	Ward Brown, M.D.	Yes
13	Anthony DeFranco, M.D., FACC	No
14	Ronald Diamond, M.D.	Yes

Drug Classes for Review

ALZHEIMERS AGENTS

ANTIDEPRESSANTS, OTHER

ANTIDEPRESSANTS, SSRIs

ANTIPARKINSONS AGENTS

ANTIPSYCHOTICS

STIMULANTS AND RELATED AGENTS

ANALGESICS-ANESTHETICS, TOPICAL

NSAIDS

CYTOKINE AND CAM ANTAGONISTS

BONE RESORPTION SUPPRESSION AND RELATED AGENTS

PANCREATIC ENZYMES

BILE SALTS

PLATELET AGGREGATION INHIBITORS

ANDROGENIC AGENTS

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

ANTIEMETICS

ANTIBIOTICS, INHALED

ANTIBIOTICS, VAGINAL

ANTIHYPERTENSIVES

CEPHALOSPORINS AND RELATED ANTIBIOTICS

FLUOROQUINOLONES, ORAL

MACROLIDES-KETOLIDES

TETRACYCLINES

ANTIFUNGALS, ORAL

ANTIFUNGALS, TOPICAL

ANTIPARASITICS, TOPICAL

ANTIVIRALS, ORAL

ANTIVIRALS, TOPICAL

STEROIDS, TOPICAL LOW

STEROIDS, TOPICAL MEDIUM

STEROIDS, TOPICAL HIGH

STEROIDS, TOPICAL VERY HIGH

ATOPIC DERMATITIS

BRONCHODILATORS, ANTICHOLINERGIC

BRONCHODILATORS, BETA AGONIST

GLUCOCORTICOIDS, INHALED

INTRANASAL RHINITIS AGENT

LEUKOTRIENE MODIFIERS

OPHTHALMIC ANTIBIOTICS

OPHTHALMICS, ANTI-INFLAMMATORIES

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

OPHTHALMICS, GLAUCOMA AGENTS

EPINEPHRINE, SELF-INJECTED

1.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ALZHEIMERS AGENTS	ARICEPT / ARICEPT ODT (ORAL)	55.8%	ON	Yes			
ALZHEIMERS AGENTS	EXELON (TRANSDERM.)	3.9%	ON	Yes			
ALZHEIMERS AGENTS	NAMENDA (ORAL)	33.7%	ON	Yes			
ALZHEIMERS AGENTS	GALANTAMINE (ORAL)	1.9%	ON	No-Generic			
ALZHEIMERS AGENTS	EXELON CAPSULES (ORAL)	2.8%	ON	No			
ALZHEIMERS AGENTS	GALANTAMINE ER (ORAL)	1.9%	ON	No-Generic			
ALZHEIMERS AGENTS	RAZADYNE SOLUTION (ORAL)	0.0%	OFF	No			
ALZHEIMERS AGENTS	EXELON SOLUTION (ORAL)	0.0%	OFF	No			

- Discussion:
- Dr. Boblin made a motion to accept staff recommendations, including grandfathering all drugs moving to a non-preferred status.
 - Second –Ward Brown
 - All members were in favor of this motion.
 - Motion passes.
 - Ron Diamond was absent for the vote.

2. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIDEPRESSANTS, OTHER	TRAZODONE (ORAL)	26.0%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	MIRTAZAPINE (ORAL)	12.0%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	MARPLAN (ORAL)	0.0%	ON	Yes			
ANTIDEPRESSANTS, OTHER	BUPROPION (ORAL)	1.7%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	VENLAFAXINE (ORAL)	3.1%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	BUPROPION SR (ORAL)	14.5%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	NARDIL (ORAL)	0.0%	ON	Yes			
ANTIDEPRESSANTS, OTHER	BUPROPION XL (ORAL)	11.7%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	VENLAFAXIN ER TABLETS (GENERIC) (ORAL)	0.0%	OFF	No-Generic			
ANTIDEPRESSANTS, OTHER	NEFAZODONE (ORAL)	0.2%	OFF	No-Generic			
ANTIDEPRESSANTS, OTHER	PRISTIQ (ORAL)	1.1%	OFF	No			
ANTIDEPRESSANTS, OTHER	EFFEXOR XR (ORAL)	19.9%	ON	Yes			
ANTIDEPRESSANTS, OTHER	VENLAFAXIN ER TABLETS (ORAL)	0.2%	OFF	No			
ANTIDEPRESSANTS, OTHER	TRANLYCYPROMINE SULFATE (ORAL)	0.0%	ON	Yes-Generic			
ANTIDEPRESSANTS, OTHER	CYMBALTA (ORAL)	9.6%	OFF	No			
ANTIDEPRESSANTS, OTHER	VENLAFAXIN ER CAPSULES (ORAL)	0.0%	OFF	No-Generic			
ANTIDEPRESSANTS, OTHER	APLENZIN (ORAL)	0.0%	OFF	No			
ANTIDEPRESSANTS, OTHER	EMSAM (TRANSDERMAL)	0.0%	OFF	No			

- Discussion:
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – Al Liegel
 - All members were in favor of this motion.
 - Motion passes.
 - Ron Diamond was absent for the vote.

3. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIDEPRESSANTS, SSRIs	CITALOPRAM (ORAL)	27.6%	ON	Yes-Generic			
ANTIDEPRESSANTS, SSRIs	FLUOXETINE (ORAL)	26.1%	ON	Yes-Generic			
ANTIDEPRESSANTS, SSRIs	SERTRALINE (ORAL)	27.5%	ON	Yes-Generic			
ANTIDEPRESSANTS, SSRIs	PAROXETINE (ORAL)	10.8%	ON	Yes-Generic			
ANTIDEPRESSANTS, SSRIs	FLUVOXAMINE (ORAL)	0.7%	ON	Yes-Generic			
ANTIDEPRESSANTS, SSRIs	LEXAPRO (ORAL)	6.9%	OFF	No			
ANTIDEPRESSANTS, SSRIs	PEXEVA (ORAL)	0.0%	OFF	No			
ANTIDEPRESSANTS, SSRIs	PAROXETINE CR (ORAL)	0.2%	OFF	No-Generic			
ANTIDEPRESSANTS, SSRIs	FLUOXETINE WEEKLY (ORAL)	0.1%	OFF	No-Generic			
ANTIDEPRESSANTS, SSRIs	LUVOX CR (ORAL)	0.0%	OFF	No			
ANTIDEPRESSANTS, SSRIs	PAXIL SUSPENSION (ORAL)	0.0%	ON	Yes			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – James Boblin
 - All members were in favor of this motion.
 - Motion passes.
 - Ron Diamond was absent for the vote.

4. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIPARKINSONS AGENTS	BENZTROPINE (ORAL)	33.2%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	TRIHENXYPHENIDYL (ORAL)	6.2%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	CARBIDOPA / LEVODOPA (ORAL)	20.8%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	ROPINIROLE (ORAL)	28.3%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	MIRAPEX (ORAL)	4.8%	OFF	No			
ANTIPARKINSONS AGENTS	CARBIDOPA / LEVODOPA ODT (ORAL)	0.1%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	ZELAPAR (ORAL)	0.0%	OFF	No			
ANTIPARKINSONS AGENTS	SELEGILINE (ORAL)	0.3%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	BROMOCRIPTINE (ORAL)	1.0%	ON	Yes-Generic			
ANTIPARKINSONS AGENTS	PRAMIPEXOLE (ORAL)	3.5%	OFF	No-Generic			
ANTIPARKINSONS AGENTS	STALEVO (ORAL)	0.9%	ON	Yes			
ANTIPARKINSONS AGENTS	COMTAN (ORAL)	0.3%	OFF	No			

ANTIPARKINSONS AGENTS	MIRAPEX ER (ORAL)	0.0%	OFF	No			
ANTIPARKINSONS AGENTS	AZILECT (ORAL)	0.2%	OFF	No			
ANTIPARKINSONS AGENTS	TASMAR (ORAL)	0.0%	OFF	No			
ANTIPARKINSONS AGENTS	REQUIP XL (ORAL)	0.4%	ON	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Kevin Izard
 - All members were in favor of this motion.
 - Motion passes.

5. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIPSYCHOTICS	FLUPHENAZINE (ORAL)	0.9%	ON	Yes-Generic			
ANTIPSYCHOTICS	THIOTHIXENE (ORAL)	0.6%	ON	Yes-Generic			
ANTIPSYCHOTICS	THIORIDAZINE (ORAL)	0.4%	ON	No-Generic			
ANTIPSYCHOTICS	HALOPERIDOL (ORAL)	3.1%	ON	Yes-Generic			
ANTIPSYCHOTICS	CHLORPROMAZINE (ORAL)	0.8%	ON	Yes-Generic			
ANTIPSYCHOTICS	AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.1%	ON	Yes-Generic			
ANTIPSYCHOTICS	RISPERIDONE (ORAL)	26.2%	ON	Yes-Generic			
ANTIPSYCHOTICS	TRIFLUOPERAZINE (ORAL)	0.3%	ON	Yes-Generic			
ANTIPSYCHOTICS	ORAP (ORAL)	0.1%	ON	Yes			
ANTIPSYCHOTICS	PERPHENAZINE (ORAL)	0.4%	ON	Yes-Generic			
ANTIPSYCHOTICS	CLOZAPINE (ORAL)	2.8%	ON	Yes-Generic			
ANTIPSYCHOTICS	MOBAN (ORAL)	0.1%	ON	Yes			
ANTIPSYCHOTICS	SEROQUEL (ORAL)	28.5%	ON	Yes			
ANTIPSYCHOTICS	GEODON (ORAL)	9.9%	ON	Yes			
ANTIPSYCHOTICS	FANAPT (ORAL)	0.0%	OFF	No			
ANTIPSYCHOTICS	SAPHRIS (SUBLINGUAL)	0.0%	OFF	No			
ANTIPSYCHOTICS	SEROQUEL XR (ORAL)	1.2%	OFF	No			
ANTIPSYCHOTICS	SYMBYAX (ORAL)	0.1%	OFF	No			
ANTIPSYCHOTICS	FAZACLO (ORAL)	0.1%	OFF	No			
ANTIPSYCHOTICS	INVEGA (ORAL)	1.2%	OFF	No			
ANTIPSYCHOTICS	ABILIFY (ORAL)	16.2%	OFF	No			
ANTIPSYCHOTICS	ZYPREXA (ORAL)	7.0%	OFF	No			

- Discussion:
- Dr. Diamond made a motion to accept staff recommendations as presented and directed staff to consider making Abilify a preferred agent following further evaluation of the cost to the State.
 - Second – Al Liegel
 - The vote was 8 - 2 in favor of the motion. Pat Towers and Ward Brown voted nay.
 - Motion passes.

6. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
STIMULANTS AND RELATED AGENTS	METHYLPHENIDATE (ORAL)	8.7%	ON	Yes-Generic			
STIMULANTS AND RELATED AGENTS	AMPHETAMINE SALT COMBO (ORAL)	15.6%	ON	Yes-Generic			
STIMULANTS AND RELATED AGENTS	METHYLPHENIDATE ER (ORAL)	2.0%	ON	Yes-Generic			
STIMULANTS AND RELATED AGENTS	DEXMETHYLPHENIDATE (ORAL)	0.9%	ON	Yes-Generic			
STIMULANTS AND RELATED AGENTS	VYVANSE (ORAL)	12.1%	ON	Yes			
STIMULANTS AND RELATED AGENTS	DESOXYN (ORAL)	0.0%	NR	No			
STIMULANTS AND RELATED AGENTS	METHYLIN CHEWABLE AND SOLUTION (ORAL)	0.2%	ON	No			
STIMULANTS AND RELATED AGENTS	FOCALIN XR (ORAL)	4.9%	ON	Yes			
STIMULANTS AND RELATED AGENTS	DAYTRANA (TRANSDERMAL)	1.2%	ON	Yes			
STIMULANTS AND RELATED AGENTS	CONCERTA (ORAL)	16.5%	ON	Yes			
STIMULANTS AND RELATED AGENTS	METADATE CD (ORAL)	2.4%	ON	Yes			
STIMULANTS AND RELATED AGENTS	DEXTROAMPHETAMINE (ORAL)	2.6%	ON	No-Generic		Yes	
STIMULANTS AND RELATED AGENTS	RITALIN LA (ORAL)	0.9%	OFF	No			
STIMULANTS AND RELATED AGENTS	INTUNIV (ORAL)	0.7%	OFF	No			
STIMULANTS AND RELATED AGENTS	STRATTERA (ORAL)	4.5%	OFF	No			
STIMULANTS AND RELATED AGENTS	AMPHETAMINE SALT COMBO ER (ORAL)	19.7%	ON	Yes-Generic			
STIMULANTS AND RELATED AGENTS	PROCENTRA (ORAL)	0.0%	OFF	No			
STIMULANTS AND RELATED AGENTS	NUVIGIL (ORAL)	0.0%	OFF	No			
STIMULANTS AND RELATED AGENTS	PROVIGIL (ORAL)	0.5%	OFF	No			
STIMULANTS AND RELATED AGENTS	METHAMPHETAMINE (ORAL)	0.0%	OFF	No-Generic			

- Discussion:

- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Alicia Walker
 - All members were in favor of this motion.
 - Motion passes.

7.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANALGESICS-ANESTHETICS, TOPICAL	CAPSAICIN OTC (TOPICAL)	1.8%	NR	Yes-Generic			
ANALGESICS-ANESTHETICS, TOPICAL	VOLTAREN (TOPICAL)	20.4%	ON	Yes			
ANALGESICS-ANESTHETICS, TOPICAL	LIDODERM (TOPICAL)	75.3%	ON	Yes			
ANALGESICS-ANESTHETICS, TOPICAL	FLECTOR (TOPICAL)	2.5%	OFF	No			
ANALGESICS-ANESTHETICS, TOPICAL	PENNSAID (TOPICAL)	0.0%	OFF	No			

- Discussion:

- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – Ward Brown
 - All members were in favor of this motion.
 - Motion passes.

8.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
NSAIDS	MELOXICAM (ORAL)	7.8%	ON	Yes-Generic			
NSAIDS	PIROXICAM (ORAL)	1.5%	ON	Yes-Generic			
NSAIDS	IBUPROFEN RX (ORAL)	45.7%	ON	Yes-Generic			
NSAIDS	KETOROLAC (ORAL)	1.8%	ON	Yes-Generic			
NSAIDS	NAPROXEN (ORAL)	21.4%	ON	Yes-Generic			
NSAIDS	FLURBIPROFEN (ORAL)	0.1%	ON	Yes-Generic			
NSAIDS	KETOPROFEN (ORAL)	0.5%	ON	Yes-Generic			
NSAIDS	OXAPROZIN (ORAL)	0.1%	OFF	No-Generic			
NSAIDS	INDOMETHACIN (ORAL/RECTAL)	2.6%	ON	Yes-Generic			
NSAIDS	DICLOFENAC (ORAL)	9.2%	ON	Yes-Generic			
NSAIDS	ETODOLAC (ORAL)	0.2%	OFF	No-Generic			
NSAIDS	FENOPROFEN (ORAL)	0.0%	OFF	No-Generic			
NSAIDS	SULINDAC (ORAL)	0.1%	OFF	No-Generic			
NSAIDS	NABUMETONE (ORAL)	4.1%	ON	Yes-Generic			
NSAIDS	VIMOVO (ORAL)	0.0%	NR	No			

NSAIDS	INDOCIN SUSPENSION (ORAL)	0.0%	NR	No			
NSAIDS	ARTHROTEC (ORAL)	0.2%	OFF	No			
NSAIDS	CELEBREX (ORAL)	4.5%	OFF	No			
NSAIDS	MECLOFENAMATE (ORAL)	0.0%	ON	Yes-Generic			
NSAIDS	TOLMETIN (ORAL)	0.0%	OFF	No-Generic			
NSAIDS	MEFENAMIC ACID (ORAL)	0.0%	NR	No-Generic			
NSAIDS	ZIPSOR (ORAL)	0.0%	NR	No			

- Discussion:
- Dr. Izard made a motion to accept staff recommendations as presented.
 - Motion – Kevin Izard
 - Second – Al Liegel
 - All members were in favor of this motion.
 - Motion passes.

9. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CYTOKINE AND CAM ANTAGONISTS	KINERET (INJECTION)	0.9%	ON	No			
CYTOKINE AND CAM ANTAGONISTS	ENBREL (INJECTION)	38.9%	ON	Yes			
CYTOKINE AND CAM ANTAGONISTS	HUMIRA (INJECTION)	55.7%	ON	Yes			
CYTOKINE AND CAM ANTAGONISTS	CIMZIA (INJECTION)	3.9%	ON	Yes			
CYTOKINE AND CAM ANTAGONISTS	SIMPONI (INJECTION)	0.6%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Catherine Decker
 - All members were in favor of this motion.
 - Motion passes.

10. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	MIACALCIN (NASAL)	3.3%	ON	Yes			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	ALENDRONATE TABLETS (ORAL)	84.6%	ON	Yes-Generic			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	ACTONEL (ORAL)	3.5%	OFF	No			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	FOSAMAX PLUS D (ORAL)	0.8%	OFF	No			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	EVISTA (ORAL)	3.8%	OFF	No			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	BONIVA (ORAL)	3.1%	OFF	No			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	FOSAMAX SOLUTION (ORAL)	0.1%	OFF	No			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	FORTICAL (NASAL)	0.1%	OFF	No			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	CALCITONIN SALMON (NASAL)	0.5%	OFF	No-Generic			
BONE RESORPTION SUPPRESSION AND RELATED AGENTS	ETIDRONATE DISODIUM (ORAL)	0.0%	NR	No-Generic			

- Discussion:
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – Alicia Walker
 - All members were in favor of this motion.
 - Motion passes.

11. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PANCREATIC ENZYMES	PANCRELIPASE (ORAL)	1.4%	ON	Yes-Generic			
PANCREATIC ENZYMES	ZENPEP (ORAL)	0.1%	ON	Yes			
PANCREATIC ENZYMES	PANCREAZE (ORAL)	0.1%	NR	Yes			
PANCREATIC ENZYMES	CREON (ORAL)	31.4%	ON	NO			

- Discussion:
 - Dr. Diamond made a motion to accept staff recommendations as presented.
 - Second- James Boblin
 - Al Liegel amended to the motion to include grandfathering for members currently taking Creon.
 - Amended Motion accepted by – Ron Diamond
 - Amended Second accepted by – James Boblin
 - All members were in favor of this motion.
 - Motion passes.
-

12. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
BILE SALTS	URSODIOL (ORAL)	96.0%	NR	Yes-Generic			
BILE SALTS	URSO FORTE (ORAL)	0.4%	NR	No			
BILE SALTS	ACTIGALL (ORAL)	0.1%	NR	No			
BILE SALTS	URSO (ORAL)	3.4%	NR	No			
BILE SALTS	CHENODAL (ORAL)	0.1%	NR	No			

- Discussion: New class.
 - Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Ron Diamond
 - All members were in favor of this motion.
 - Motion passes.
-
-

13.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
PLATELET AGGREGATION INHIBITORS	TICLOPIDINE (ORAL)	0.3%	OFF	No-Generic			
PLATELET AGGREGATION INHIBITORS	DIPYRIDAMOLE (ORAL)	0.7%	ON	Yes-Generic			
PLATELET AGGREGATION INHIBITORS	AGGRENOX (ORAL)	5.6%	ON	Yes			
PLATELET AGGREGATION INHIBITORS	PLAVIX (ORAL)	93.3%	ON	Yes			
PLATELET AGGREGATION INHIBITORS	EFFIENT (ORAL)	0.1%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – James Boblin
 - All members were in favor of this motion.
 - Motion passes.

14.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANDROGENIC AGENTS	ANDRODERM (TRANSDERM.)	20.1%	ON	Yes			
ANDROGENIC AGENTS	ANDROGEL (TRANSDERM.)	76.2%	ON	Yes			
ANDROGENIC AGENTS	TESTIM (TRANSDERM.)	3.7%	OFF	No			

- Discussion:
- Dr. Izard made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of this motion.
 - Motion passes.

15.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	ONGLYZA (ORAL)	0.2%	OFF	Yes			
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	JANUMET (ORAL)	15.0%	ON	Yes			
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	JANUVIA (ORAL)	71.2%	ON	Yes			
HYPOGLYCEMICS, INCRETIN	BYETTA PENS (SUBCUTANE.)	12.9%	OFF	No			

MIMETICS/ENHANCERS							
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	SYMLIN (SUBCUTANE.)	0.2%	OFF	No			
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	SYMLIN PENS (SUBCUTANE.)	0.5%	OFF	No			
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	VICTOZA (SUBCUTANE.)	0.0%	OFF	No			

- Motion #1
- Discussion: Dr Izard indicated frustration with current Byetta PA process. The process is long and cumbersome. Dr. Izard stated that the only question on the form should be do you have diabetes. Managing diabetes is more than just managing blood sugar. Members with diabetes also have weight issues. Byetta has properties that contribute to weight loss and therefore help manage diabetes.
- Dr. Izard made a motion to accept staff recommendations as presented, but add Byetta as a preferred agent.
 - Second – Rosanne Barber
 - Kevin Izard withdrew motion.

- Motion #2
- Discussion: The Committee had further discussion regarding alternatives to paper PA. One of the options was STAT PA. Lynn Radmer, State Pharmacist Consultant, discussed the drawbacks of STAT-PA and how easy it is to get a PA even when submitted with contradictory information. Dr Diamond indicated that current requirement is too complicated, but no restrictions would make it too easy to use as first line. Other options include simplifying the current paper PA process, use STAT-PA, or place diagnosis restrictions on Byetta. Byetta should remain NP, but simplify the PA process allowing easier access to Byetta. .
- Steve Maike made a second motion to accept staff recommendations as presented, but modify the Byetta PA process.
 - Second – Ward Brown
 - The vote was 8 - 2 in favor of the motion. James Boblin and Kevin Izard voted against the motion.
 - Motion passes.

16.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	HUMALOG MIX (SUBCUTANE.)	2.1%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	HUMULIN (SUBCUTANE.)	15.9%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLIN PENS (SUBCUTANE.)	0.1%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	HUMALOG (SUBCUTANE.)	17.4%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLOG MIX 70/30 PENS (SUBCUTANE.)	0.4%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLOG MIX 70/30 (SUBCUTANE.)	0.1%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLOG (SUBCUTANE.)	0.8%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	LANTUS (SUBCUTANE.)	25.9%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLIN (SUBCUTANE.)	0.2%	OFF	No			

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLOG PENS (SUBCUTANE.)	1.0%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	HUMALOG PENS (SUBCUTANE.)	13.4%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	LEVEMIR (SUBCUTANE.)	0.8%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	HUMALOG MIX PENS (SUBCUTANE.)	2.5%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	LEVEMIR PENS (SUBCUTANE.)	1.4%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	LANTUS PENS (SUBCUTANE.)	15.8%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	HUMULIN PENS (SUBCUTANE.)	2.1%	ON	Yes			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	APIDRA PENS (SUBCUTANE.)	0.1%	OFF	No			
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	APIDRA (SUBCUTANE.)	0.1%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Al Liegel
 - All members were in favor of this motion.
 - Motion passes.

17. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIEMETICS	ONDANSETRON / ODT (ORAL)	96.8%	ON	Yes-Generic			
ANTIEMETICS	MARINOL (ORAL)	0.4%	ON	Yes			
ANTIEMETICS	SANCUSO (TRANSDERMAL)	0.2%	ON	Yes			
ANTIEMETICS	EMEND (ORAL)	1.8%	ON	Yes			
ANTIEMETICS	ANZEMET (ORAL)	0.0%	OFF	No			
ANTIEMETICS	GRANISETRON (ORAL)	0.2%	OFF	No-Generic			
ANTIEMETICS	CESAMET (ORAL)	0.0%	OFF	No			
ANTIEMETICS	DRONABINOL (ORAL)	0.6%	OFF	No-Generic			

- Discussion:
- Dr. Boblin made a motion to accept staff recommendations.
 - Second – Steve Maike
 - All members were in favor of this motion.
 - Motion passes.
 - Kevin Izard was absent for the vote.

18. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIBIOTICS, INHALED	TOBI (INHALATION)	98.9%	NR	Yes			
ANTIBIOTICS, INHALED	CAYSTON (INHALATION)	1.1%	NR	No			

- Discussion: New class
- The Committee made a motion to accept staff recommendations as presented.
 - Motion – James Boblin
 - Second – Al Liegel
 - All members were in favor of this motion.
 - Motion passes.
 - Kevin Izard was absent for the vote.

19. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIBIOTICS, VAGINAL	METROGEL-VAGINAL (VAGINAL)	0.2%	NR	Yes			
ANTIBIOTICS, VAGINAL	VANAZOLE (VAGINAL)	10.1%	ON	Yes			
ANTIBIOTICS, VAGINAL	METRONIDAZOLE (VAGINAL)	73.5%	ON	Yes-Generic			
ANTIBIOTICS, VAGINAL	CLINDAMYCIN (VAGINAL)	10.2%	ON	Yes-Generic			
ANTIBIOTICS, VAGINAL	CLINDESSE (VAGINAL)	0.1%	ON	No			
ANTIBIOTICS, VAGINAL	CLEOCIN OVULES (VAGINAL)	5.9%	ON	No			

- Discussion:
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second – James Boblin
 - All members in favor of this motion.
 - Motion passes.
 - Kevin Izard was absent for the vote.

20. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIHYPURICEMICS	ALLOPURINOL (ORAL)	77.6%	ON	Yes-Generic			
ANTIHYPURICEMICS	COLCHICINE (ORAL)	18.6%	ON	Yes-Generic			
ANTIHYPURICEMICS	PROBENECID (ORAL)	1.7%	ON	Yes-Generic			
ANTIHYPURICEMICS	PROBENECID / COLCHICINE (ORAL)	0.8%	ON	Yes-Generic			
ANTIHYPURICEMICS	COLCRYS (ORAL)	0.0%	NR	No			
ANTIHYPURICEMICS	ULORIC (ORAL)	1.4%	OFF	No			

- Discussion:
- Pat Towers made a motion to accept staff recommendations.
 - Second – Al Liegel
 - All members were in favor of this motion.
 - Motion passes.
 - Kevin Izard was absent for the vote.

21. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEPHALEXIN (ORAL)	23.3%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFUROXIME (ORAL)	4.1%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	SUPRAX (ORAL)	0.9%	ON	Yes			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	AUGMENTIN 125 SUSPENSION (ORAL)	0.1%	ON	Yes			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	AMOXICILLIN/CLAV TABLET (ORAL)	24.3%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFADROXIL (ORAL)	1.6%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	AMOXICILLIN/CLAV SUSPENSION (ORAL)	21.4%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	AUGMENTIN 250 SUSPENSION (ORAL)	0.2%	ON	Yes			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFACLOR (ORAL)	0.1%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFPROZIL (ORAL)	4.5%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFDINIR (ORAL)	19.2%	ON	Yes-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEDAX (ORAL)	0.0%	OFF	No			
CEPHALOSPORINS AND RELATED	AUGMENTIN XR (ORAL)	0.0%	OFF	No			

ANTIBIOTICS							
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFTIN SUSPENSION (ORAL)	0.0%	OFF	No			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFPODOXIME (ORAL)	0.4%	ON	No-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	AMOXICILLIN/CLAV XR (ORAL)	0.0%	OFF	No-Generic			
CEPHALOSPORINS AND RELATED ANTIBIOTICS	CEFDITOREN (ORAL)	0.0%	OFF	No-Generic			

- Discussion:
- Dr. Diamond made a motion to accept staff recommendations as presented.
 - Second – Ward Brown
 - All members were in favor of the motion.
 - Motion passes.

22. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
FLUOROQUINOLONES, ORAL	CIPROFLOXACIN TABLETS (ORAL)	74.1%	ON	Yes-Generic			
FLUOROQUINOLONES, ORAL	FACTIVE (ORAL)	0.0%	OFF	No			
FLUOROQUINOLONES, ORAL	PROQUIN XR (ORAL)	0.0%	OFF	No			
FLUOROQUINOLONES, ORAL	LEVAQUIN (ORAL)	14.1%	OFF	OFF			
FLUOROQUINOLONES, ORAL	AVELOX (ORAL)	11.5%	ON	ON			
FLUOROQUINOLONES, ORAL	NOROXIN (ORAL)	0.0%	OFF	No			
FLUOROQUINOLONES, ORAL	CIPRO SUSPENSION (ORAL)	0.3%	OFF	No			
FLUOROQUINOLONES, ORAL	CIPROFLOXACIN ER (ORAL)	0.0%	OFF	No-Generic			
FLUOROQUINOLONES, ORAL	OFLOXACIN (ORAL)	0.0%	OFF	No-Generic			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Ron Diamond
 - All members were in favor of the motion.
 - Motion passes.

23. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
MACROLIDES-KETOLIDES	ERYTHROMYCIN (ORAL)	0.8%	ON	Yes-Generic			
MACROLIDES-KETOLIDES	CLARITHROMYCIN (ORAL)	3.5%	ON	Yes-Generic			
MACROLIDES-KETOLIDES	AZITHROMYCIN (ORAL)	95.7%	ON	Yes-Generic			
MACROLIDES-KETOLIDES	ZMAX (ORAL)	0.0%	OFF	No			
MACROLIDES-	CLARITHROMYCIN	0.0%	OFF	No-Generic			

KETOLIDES	ER (ORAL)						
MACROLIDES-KETOLIDES	KETEK (ORAL)	0.0%	OFF	No			

- Discussion:
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second – Kevin Izard
 - All members were in favor of the motion.
 - Motion passes.

24.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
TETRACYCLINES	DOXYCYCLINE HYCLATE (ORAL)	62.5%	ON	Yes-Generic			
TETRACYCLINES	TETRACYCLINE (ORAL)	12.2%	ON	Yes-Generic			
TETRACYCLINES	MINOCYCLINE CAPSULES (ORAL)	20.1%	ON	Yes-Generic			
TETRACYCLINES	ORACEA (ORAL)	0.1%	OFF	No			
TETRACYCLINES	DOXYCYCLINE MONOHYDRATE (ORAL)	3.2%	ON	No-Generic			
TETRACYCLINES	VIBRAMYCIN SUSPENSION (ORAL)	0.2%	NR	No			
TETRACYCLINES	NUTRIDOX (ORAL)	0.0%	OFF	No			
TETRACYCLINES	DOXYCYCLINE HYCLATE DR (ORAL)	0.0%	ON	No-Generic			
TETRACYCLINES	MINOCYCLINE TABLETS (ORAL)	0.2%	ON	No-Generic			
TETRACYCLINES	SOLODYN (ORAL)	0.1%	OFF	No			
TETRACYCLINES	DORYX (ORAL)	0.8%	NR	No			
TETRACYCLINES	ADOXA TT (ORAL)	0.0%	OFF	No			
TETRACYCLINES	DEMECLOCYCLINE (ORAL)	0.2%	OFF	No-Generic			
TETRACYCLINES	MINOCYCLINE ER (ORAL)	0.4%	ON	No-Generic			
TETRACYCLINES	ADOXA CK (ORAL)	0.0%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Rosanne Barber
 - All members were in favor of the motion.
 - Motion passes.

25.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIFUNGALS, ORAL	FLUCONAZOLE (ORAL)	65.8%	ON	Yes-Generic			
ANTIFUNGALS, ORAL	KETOCONAZOLE (ORAL)	1.4%	ON	NO-Generic			
ANTIFUNGALS, ORAL	TERBINAFINE (ORAL)	4.0%	ON	Yes-Generic			
ANTIFUNGALS, ORAL	NYSTATIN (ORAL)	20.2%	ON	Yes-Generic			
ANTIFUNGALS, ORAL	GRIS-PEG (ORAL)	1.0%	ON	Yes			

ANTIFUNGALS, ORAL	CLOTRIMAZOLE (MUCOUS MEM)	0.2%	OFF	No-Generic			
ANTIFUNGALS, ORAL	GRISEOFULVIN SUSPENSION (ORAL)	6.4%	ON	Yes-Generic			
ANTIFUNGALS, ORAL	GRIFULVIN V TABLETS (ORAL)	0.1%	OFF	No			
ANTIFUNGALS, ORAL	ORAVIG (BUCCAL)	0.0%	NR	No			
ANTIFUNGALS, ORAL	LAMISIL GRANULES (ORAL)	0.1%	OFF	No			
ANTIFUNGALS, ORAL	ANCOBON (ORAL)	0.0%	ON	Yes			
ANTIFUNGALS, ORAL	ITRACONAZOLE (ORAL)	0.3%	ON	Yes-Generic			
ANTIFUNGALS, ORAL	VFEND (ORAL)	0.3%	OFF	No			
ANTIFUNGALS, ORAL	NOXAFIL (ORAL)	0.0%	OFF	No			

- Discussion:

- Al Liegel made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion.
 - Motion passes.

26. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIFUNGALS, TOPICAL	TOLNAFTATE OTC (TOPICAL)	0.3%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	NYSTATIN-TRIAMCINOLONE (TOPICAL)	6.9%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	MICONAZOLE OTC (TOPICAL)	2.6%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	CLOTRIMAZOLE OTC (TOPICAL)	5.8%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	CLOTRIMAZOLE RX (TOPICAL)	10.4%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	NAFTIN (TOPICAL)	0.1%	OFF	No			
ANTIFUNGALS, TOPICAL	NYSTATIN (TOPICAL)	34.5%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	TERBINAFINE OTC (TOPICAL)	2.2%	ON	No-Generic		Non-Covered OTC	
ANTIFUNGALS, TOPICAL	CLOTRIMAZOLE-BETAMETHASONE (TOPICAL)	12.5%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	ECONAZOLE (TOPICAL)	3.2%	ON	No-Generic			
ANTIFUNGALS, TOPICAL	KETOCONAZOLE (TOPICAL)	11.3%	ON	NO-Generic			
ANTIFUNGALS, TOPICAL	KETOCONAZOLE SHAMPOO (TOPICAL)	9.9%	ON	Yes-Generic			
ANTIFUNGALS, TOPICAL	MENTAX (TOPICAL)	0.0%	OFF	No			
ANTIFUNGALS, TOPICAL	OXISTAT (TOPICAL)	0.1%	OFF	No			
ANTIFUNGALS, TOPICAL	ERTACZO (TOPICAL)	0.0%	OFF	No			

ANTIFUNGALS, TOPICAL	CICLOPIROX CR/SUSP/GEL (TOPICAL)	0.1%	OFF	No-Generic			
ANTIFUNGALS, TOPICAL	EXELDERM (TOPICAL)	0.0%	OFF	No			
ANTIFUNGALS, TOPICAL	XOLEGEL (TOPICAL)	0.0%	OFF	No			
ANTIFUNGALS, TOPICAL	VUSION (TOPICAL)	0.0%	OFF	No			
ANTIFUNGALS, TOPICAL	CICLOPIROX SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
ANTIFUNGALS, TOPICAL	BENSAL HP (TOPICAL)	0.0%	OFF	No			
ANTIFUNGALS, TOPICAL	CNL 8 (TOPICAL)	0.0%	OFF	No			
ANTIFUNGALS, TOPICAL	EXTINA (TOPICAL)	0.0%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – James Boblin
 - Nine members were in favor of this motion.
 - Alicia Walker voted against the motion.
 - Motion passes.

27. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIPARASITICS, TOPICAL	PERMETHRIN OTC (TOPICAL)	15.6%	ON	Yes-Generic			
ANTIPARASITICS, TOPICAL	PERMETHRIN (TOPICAL)	75.4%	ON	Yes-Generic			
ANTIPARASITICS, TOPICAL	EURAX (TOPICAL)	1.6%	ON	NO			
ANTIPARASITICS, TOPICAL	OVIDE (TOPICAL)	5.8%	ON	NO			
ANTIPARASITICS, TOPICAL	ULESFIA (TOPICAL)	0.1%	OFF	No			
ANTIPARASITICS, TOPICAL	MALATHION (TOPICAL)	1.1%	OFF	No-Generic			
ANTIPARASITICS, TOPICAL	LINDANE (TOPICAL)	0.4%	OFF	No-Generic			

- Discussion:
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of the motion.
 - Motion passes.

28. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIVIRALS, ORAL	ACYCLOVIR (ORAL)	26.9%	ON	Yes-Generic			
ANTIVIRALS, ORAL	RIMANTADINE (ORAL)	0.0%	ON	Yes-Generic			
ANTIVIRALS, ORAL	AMANTADINE (ORAL)	5.1%	ON	Yes-Generic			

ANTIVIRALS, ORAL	VALTREX (ORAL)	56.0%	ON	Yes			
ANTIVIRALS, ORAL	TAMIFLU (ORAL)	5.4%	ON	Yes			
ANTIVIRALS, ORAL	RELENZA (INHALATION)	0.1%	ON	Yes			
ANTIVIRALS, ORAL	FAMVIR (ORAL)	1.3%	ON	Yes			
ANTIVIRALS, ORAL	FAMCICLOVIR (ORAL)	0.9%	OFF	No-Generic			
ANTIVIRALS, ORAL	VALACYCLOVIR (ORAL)	4.4%	OFF	No-Generic			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Kevin Izard
 - All members were in favor of the motion.
 - Motion passes.

29. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ANTIVIRALS, TOPICAL	DENAVIR (TOPICAL)	27.4%	ON	Yes			
ANTIVIRALS, TOPICAL	ZOVIRAX OINTMENT (TOPICAL)	69.2%	ON	Yes			
ANTIVIRALS, TOPICAL	ZOVIRAX CREAM (TOPICAL)	3.3%	OFF	No			

- Discussion:
- Dr. Izard made a motion to accept staff recommendations as presented.
 - Second – Catherine Decker
 - All members were in favor of the motion.
 - Motion passes.

30. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
STEROIDS, TOPICAL LOW	CAPEX SHAMPOO (TOPICAL)	0.7%	NR	Yes			
STEROIDS, TOPICAL LOW	HYDROCORTISONE (TOPICAL)	77.7%	ON	Yes-Generic			
STEROIDS, TOPICAL LOW	DESONIDE (TOPICAL)	18.8%	ON	Yes-Generic			
STEROIDS, TOPICAL LOW	ALCLOMETASONE DIPROPIONATE (TOPICAL)	0.1%	OFF	No-Generic			
STEROIDS, TOPICAL LOW	DERMA-SMOOTHES-FS (TOPICAL)	2.7%	NR	No			
STEROIDS, TOPICAL LOW	PEDIADERM HC (TOPICAL)	0.0%	OFF	No			
STEROIDS, TOPICAL LOW	VERDESO (TOPICAL)	0.0%	OFF	No			
STEROIDS, TOPICAL LOW	DESONATE (TOPICAL)	0.0%	OFF	No			

- Discussion:

- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Al Liegel
 - All members were in favor of the motion.
 - Motion passes.

31. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
STERIODS, TOPICAL MEDIUM	LOCOID LIPOCREAM (TOPICAL)	0.0%	OFF	No			
STERIODS, TOPICAL MEDIUM	FLUOCINOLONE ACETONIDE (TOPICAL)	14.5%	ON	Yes-Generic			
STERIODS, TOPICAL MEDIUM	FLUTICASONE PROPIONATE (TOPICAL)	24.0%	ON	Yes-Generic			
STERIODS, TOPICAL MEDIUM	HYDROCORTISONE VALERATE (TOPICAL)	19.3%	ON	Yes-Generic			
STERIODS, TOPICAL MEDIUM	PANDEL (TOPICAL)	0.0%	OFF	No			
STERIODS, TOPICAL MEDIUM	PREDNICARBATE (TOPICAL)	0.0%	OFF	No-Generic			
STERIODS, TOPICAL MEDIUM	HYDROCORTISONE BUTYRATE (TOPICAL)	2.9%	ON	No-Generic			
STERIODS, TOPICAL MEDIUM	MOMETASONE FUROATE (TOPICAL)	35.5%	ON	No-Generic			
STERIODS, TOPICAL MEDIUM	CLODERM (TOPICAL)	0.2%	OFF	No			
STERIODS, TOPICAL MEDIUM	CORDRAN TAPE (TOPICAL)	0.4%	OFF	No			
STERIODS, TOPICAL MEDIUM	LUXIQ (TOPICAL)	2.0%	ON	No			
STERIODS, TOPICAL MEDIUM	CUTIVATE LOTION (TOPICAL)	1.2%	NR	No			
STERIODS, TOPICAL MEDIUM	MOMEXIN (TOPICAL)	0.0%	OFF	No			

- Discussion:

- Dr. Izard made a motion to accept staff recommendations as presented.
 - Second – Rosanne Barber
 - All members were in favor of the motion.
 - Motion passes.

32. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
STERIODS, TOPICAL HIGH	BETAMETHASONE VALERATE (TOPICAL)	2.5%	ON	Yes-Generic			
STERIODS, TOPICAL HIGH	TRIAMCINOLONE ACETONIDE (TOPICAL)	78.1%	ON	Yes-Generic			
STERIODS, TOPICAL HIGH	FLUOCINONIDE (TOPICAL)	8.2%	ON	Yes-Generic			

STEROIDS, TOPICAL HIGH	FLUOCINONIDE-E (TOPICAL)	0.2%	ON	Yes-Generic			
STEROIDS, TOPICAL HIGH	FLUOCINONIDE EMOLLIENT (TOPICAL)	0.2%	ON	Yes-Generic			
STEROIDS, TOPICAL HIGH	BETAMETHASONE DIPROPIONATE (TOPICAL)	10.1%	ON	Yes-Generic			
STEROIDS, TOPICAL HIGH	DIFLORASONE DIACETATE (TOPICAL)	0.2%	ON	No-Generic			
STEROIDS, TOPICAL HIGH	AMCINONIDE (TOPICAL)	0.0%	OFF	No-Generic			
STEROIDS, TOPICAL HIGH	KENALOG AEROSOL (TOPICAL)	0.1%	OFF	No			
STEROIDS, TOPICAL HIGH	HALOG (TOPICAL)	0.0%	OFF	No			
STEROIDS, TOPICAL HIGH	VANOS (TOPICAL)	0.0%	OFF	No			
STEROIDS, TOPICAL HIGH	DESOXIMETASONE (TOPICAL)	0.5%	OFF	No-Generic			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion.
 - Motion passes.

33.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
STEROIDS, TOPICAL VERY HIGH	CLOBETASOL PROPIONATE (TOPICAL)	88.5%	ON	Yes-Generic			
STEROIDS, TOPICAL VERY HIGH	CLOBETASOL EMOLLIENT (TOPICAL)	3.6%	ON	Yes-Generic			
STEROIDS, TOPICAL VERY HIGH	HALOBETASOL PROPIONATE (TOPICAL)	6.6%	ON	Yes-Generic			
STEROIDS, TOPICAL VERY HIGH	HALONATE PAC (TOPICAL)	0.0%	OFF	No-Generic			
STEROIDS, TOPICAL VERY HIGH	OLUX-E (TOPICAL)	0.1%	OFF	No			
STEROIDS, TOPICAL VERY HIGH	OLUX-OLUX-E (TOPICAL)	0.0%	OFF	No			
STEROIDS, TOPICAL VERY HIGH	HALONATE (TOPICAL)	0.0%	OFF	No-Generic			
STEROIDS, TOPICAL VERY HIGH	CLOBEX (TOPICAL)	1.0%	OFF	No			

- Discussion:
- Dr. Boblin made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of the motion.
 - Motion passes.

34. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
ATOPIC DERMATITIS	ELIDEL (TOPICAL)	51.4%	OFF	No			
ATOPIC DERMATITIS	PROTOPIC (TOPICAL)	48.6%	OFF	No			

- Discussion:
- Dr. Izard made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - Nine members were in favor of this motion.
 - Alicia Walker voted against the motion.
 - Motion passes.

35. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
BRONCHODILATORS, ANTICHOLINERGIC	IPRATROPIUM NEBULIZER (INHALATION)	13.6%	ON	Yes-Generic			
BRONCHODILATORS, ANTICHOLINERGIC	IPRATROPIUM / ALBUTEROL (INHALATION)	2.0%	OFF	Yes-Generic			
BRONCHODILATORS, ANTICHOLINERGIC	COMBIVENT (INHALATION)	40.1%	ON	Yes			
BRONCHODILATORS, ANTICHOLINERGIC	SPIRIVA (INHALATION)	39.7%	ON	Yes			
BRONCHODILATORS, ANTICHOLINERGIC	ATROVENT HFA (INHALATION)	4.6%	ON	Yes			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Al Liegel
 - All members were in favor of the motion.
 - Motion passes.

36. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
BRONCHODILATORS, BETA AGONIST	MAXAIR (INHALATION)	0.1%	OFF	Yes			
BRONCHODILATORS, BETA AGONIST	ALBUTEROL (ORAL)	0.9%	ON	Yes-Generic			
BRONCHODILATORS, BETA AGONIST	ALBUTEROL NEBULIZER (INHALATION)	20.8%	ON	Yes-Generic			
BRONCHODILATORS, BETA AGONIST	METAPROTERENOL (ORAL)	0.0%	OFF	No-Generic			
BRONCHODILATORS, BETA AGONIST	PROAIR HFA (INHALATION)	42.3%	ON	Yes			
BRONCHODILATORS, BETA AGONIST	VENTOLIN HFA (INHALATION)	33.3%	ON	Yes			

BRONCHODILATORS, BETA AGONIST	PROVENTIL HFA (INHALATION)	0.2%	OFF	No			
BRONCHODILATORS, BETA AGONIST	XOPENEX HFA (INHALATION)	0.6%	OFF	No			
BRONCHODILATORS, BETA AGONIST	TERBUTALINE (ORAL)	0.1%	ON	Yes-Generic			
BRONCHODILATORS, BETA AGONIST	FORADIL (INHALATION)	0.2%	ON	Yes			
BRONCHODILATORS, BETA AGONIST	ALBUTEROL NEBULIZER LOW-DOSE (INHALATION)	0.1%	OFF	No-Generic			
BRONCHODILATORS, BETA AGONIST	XOPENEX (INHALATION)	0.6%	OFF	No			
BRONCHODILATORS, BETA AGONIST	SEREVENT (INHALATION)	0.7%	ON	No	Yes		
BRONCHODILATORS, BETA AGONIST	LEVALBUTEROL (INHALATION)	0.0%	OFF	No-Generic			
BRONCHODILATORS, BETA AGONIST	PERFORMIST (INHALATION)	0.0%	OFF	No			
BRONCHODILATORS, BETA AGONIST	BROVANA (INHALATION)	0.0%	OFF	No			

- Discussion: Catherine Decker expressed concern that Serevent was recommended as non-preferred. Serevent's device is easier to use than Foradil's device and has a dose counter. Kevin IZard asked why Foradil was recommended as preferred instead of Serevent. Cost was a factor.
- Catherine Decker made a motion to accept staff recommendations and leave Serevent a preferred product.
 - Second – Alicia Walker
 - The vote was 7-3 members in favor of this motion.
 - Rosanne Barber and James Boblin voted against the motion.
 - Ron Diamond abstained from the vote.
 - Motion passes.

37. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
GLUCOCORTICIDS, INHALED	AEROBID / AEROBID-M (INHALATION)	0.3%	ON	Yes			
GLUCOCORTICIDS, INHALED	QVAR (INHALATION)	3.1%	ON	Yes			
GLUCOCORTICIDS, INHALED	FLOVENT / FLOVENT HFA (INHALATION)	22.7%	ON	Yes			
GLUCOCORTICIDS, INHALED	ALVESCO (INHALATION)	0.1%	OFF	No			
GLUCOCORTICIDS, INHALED	PULMICORT FLEXHALER (INHALATION)	1.5%	ON	Yes			
GLUCOCORTICIDS, INHALED	ADVAIR / ADVAIR HFA (INHALATION)	56.8%	ON	Yes			
GLUCOCORTICIDS, INHALED	SYMBICORT (INHALATION)	4.4%	ON	Yes			
GLUCOCORTICIDS, INHALED	ASMANEX (INHALATION)	0.6%	OFF	No			
GLUCOCORTICIDS, INHALED	PULMICORT RESPULES (INHALATION)	1.8%	OFF	No			
GLUCOCORTICIDS, INHALED	BUDESONIDE RESPULES (INHALATION)	8.6%	OFF	No-Generic			

- Discussion: Alicia Walker questioned why budesonide respules are not a preferred agent. Lynn Radmer explained it is currently preferred for a certain age group.
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Alicia Walker
 - All members were in favor of the motion.

-
- o Motion passes.
-

38. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
INTRANASAL RHINITIS AGENTS	FLUTICASONE (NASAL)	74.4%	ON	Yes-Generic			
INTRANASAL RHINITIS AGENTS	ASTELIN (NASAL)	3.0%	ON	Yes			
INTRANASAL RHINITIS AGENTS	BECONASE AQ (NASAL)	0.5%	ON	Yes			
INTRANASAL RHINITIS AGENTS	PATANASE (NASAL)	0.1%	OFF	No	Yes		
INTRANASAL RHINITIS AGENTS	ASTEPRO (NASAL)	0.7%	ON	Yes			
INTRANASAL RHINITIS AGENTS	IPRATROPIUM (NASAL)	2.0%	ON	Yes-Generic			
INTRANASAL RHINITIS AGENTS	NASACORT AQ (NASAL)	1.2%	OFF	No			
INTRANASAL RHINITIS AGENTS	NASONEX (NASAL)	15.6%	ON	No			
INTRANASAL RHINITIS AGENTS	FLUNISOLIDE (NASAL)	0.9%	ON	No-Generic		YES	
INTRANASAL RHINITIS AGENTS	VERAMYST (NASAL)	0.9%	OFF	No			
INTRANASAL RHINITIS AGENTS	OMNARIS (NASAL)	0.1%	OFF	No			
INTRANASAL RHINITIS AGENTS	RHINOCORT AQUA (NASAL)	0.6%	OFF	No			

- Discussion: Kevin Izard expressed an interest in adding Patanase as a preferred agent instead of Astepro. Ron Diamond questioned why Astepro needs to be non-preferred if Patanase is preferred.
- Dr. Izard made a motion to accept staff recommendations as presented, but make Astepro non-preferred and add Patanase as preferred. .
 - Motion – Kevin Izard
 - Second – Rosanne Barber
 - Motion withdrawn.
- Dr. Izard made a second motion to accept staff recommendations as presented and add Patanase as a preferred agent.
 - Second – Rosanne Barber
 - The vote was 6-4 members in favor of the motion.
 - Al Liegel and Pat Towers voted against the motion.
 - James Boblin and Ron Diamond abstained from the vote.
 - Motion passes.

39. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
LEUKOTRIENE MODIFIERS	ACCOLATE (ORAL)	1.4%	ON	Yes			
LEUKOTRIENE MODIFIERS	SINGULAIR (ORAL)	98.5%	ON	Yes			
LEUKOTRIENE MODIFIERS	ZYFLO CR (ORAL)	0.1%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Alicia Walker
 - All members were in favor of the motion.
 - Motion passes.

40.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OPHTHALMIC ANTIBIOTICS	SULFACETAMIDE (OPHTHALMIC)	6.5%	ON	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	TOBRAMYCIN (OPHTHALMIC)	7.1%	ON	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)	24.0%	NR	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	GENTAMICIN (OPHTHALMIC)	12.7%	ON	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	VIGAMOX (OPHTHALMIC)	15.8%	ON	Yes			
OPHTHALMIC ANTIBIOTICS	OFLOXACIN (OPHTHALMIC)	2.5%	ON	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	CIPROFLOXACIN SOLUTION (OPHTHALMIC)	8.7%	ON	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	ZYMAR (OPHTHALMIC)	4.4%	ON	No			
OPHTHALMIC ANTIBIOTICS	BESIVANCE (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMIC ANTIBIOTICS	TOBREX OINTMENT (OPHTHALMIC)	0.9%	NR	Yes			
OPHTHALMIC ANTIBIOTICS	ERYTHROMYCIN (OPHTHALMIC)	14.6%	ON	Yes-Generic			
OPHTHALMIC ANTIBIOTICS	BACITRACIN/POLYMYXIN (OPHTHALMIC)	1.1%	ON	NO-Generic			
OPHTHALMIC ANTIBIOTICS	TRIPLE ANTIBIOTIC (OPHTHALMIC)	0.9%	ON	NO-Generic			
OPHTHALMIC ANTIBIOTICS	NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	0.0%	ON	NO-Generic			
OPHTHALMIC ANTIBIOTICS	CILOXAN OINTMENT (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMIC ANTIBIOTICS	AZASITE (OPHTHALMIC)	0.3%	OFF	No			
OPHTHALMIC ANTIBIOTICS	QUIXIN (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMIC ANTIBIOTICS	BACITRACIN (OPHTHALMIC)	0.4%	ON	NO-Generic			
OPHTHALMIC ANTIBIOTICS	IQUIX (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMIC ANTIBIOTICS	NATACYN (OPHTHALMIC)	0.0%	OFF	No			

- Discussion:
- Dr. Izard made a motion to accept staff recommendations as presented.
 - Second – Ron Diamond
 - All members voted in favor of the motion.
 - Motion passes.

41.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OPHTHALMICS, ANTI-INFLAMMATORIES	LOTEMAX (OPHTHALMIC)	26.8%	ON	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	FLUOROMETHOLONE (OPHTHALMIC)	20.2%	ON	Yes-Generic			
OPHTHALMICS, ANTI-INFLAMMATORIES	FML FORTE (OPHTHALMIC)	1.0%	ON	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	FLURBIPROFEN (OPHTHALMIC)	6.0%	ON	Yes-Generic			

OPHTHALMICS, ANTI-INFLAMMATORIES	PRED MILD (OPHTHALMIC)	2.4%	ON	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	FML S.O.P. (OPHTHALMIC)	3.3%	ON	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	MAXIDEX (OPHTHALMIC)	0.3%	ON	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	FLAREX (OPHTHALMIC)	0.5%	ON	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	DEXAMETHASONE (OPHTHALMIC)	2.1%	ON	Yes-Generic			
OPHTHALMICS, ANTI-INFLAMMATORIES	DICLOFENAC (OPHTHALMIC)	28.6%	ON	Yes-Generic			
OPHTHALMICS, ANTI-INFLAMMATORIES	XIBROM (OPHTHALMIC)	2.3%	OFF	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	VEXOL (OPHTHALMIC)	0.3%	OFF	Yes			
OPHTHALMICS, ANTI-INFLAMMATORIES	NEVANAC (OPHTHALMIC)	1.2%	OFF	No			
OPHTHALMICS, ANTI-INFLAMMATORIES	KETOROLAC LS (OPHTHALMIC)	4.4%	OFF	No-Generic			
OPHTHALMICS, ANTI-INFLAMMATORIES	DUREZOL (OPHTHALMIC)	0.1%	OFF	No			
OPHTHALMICS, ANTI-INFLAMMATORIES	ACUVAIL (OPHTHALMIC)	0.5%	OFF	No			

- Discussion:
- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - The vote was 8-2 members in favor of the motion.
 - Rosanne Barber and Alicia Walker voted against the motion.
 - Motion passes.

42.Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	OPTIVAR (OPHTHALMIC)	0.6%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ALREX (OPHTHALMIC)	2.3%	ON	Yes			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	KETOTIFEN OTC (OPHTHALMIC)	18.0%	ON	Yes-Generic			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	CROMOLYN SODIUM (OPHTHALMIC)	4.5%	ON	Yes-Generic			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	PATANOL (OPHTHALMIC)	46.7%	ON	Yes			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	PATADAY (OPHTHALMIC)	25.4%	ON	Yes			

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ACULAR (OPHTHALMIC)	1.1%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ALOMIDE (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	EMADINE (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	BEPREVE (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ALOCRI (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ALAMAST (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ELESTAT (OPHTHALMIC)	0.4%	OFF	No			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	KETOROLAC (OPHTHALMIC)	0.5%	OFF	No-Generic			
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	AZELASTINE (OPHTHALMIC)	0.3%	OFF	No-Generic			

- Discussion:
- Dr. Izard made a motion to accept staff recommendations as presented.
 - Second – Al Liegel
 - All members were in favor of the motion.
 - Motion passes.

43. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
OPHTHALMICS, GLAUCOMA AGENTS	ISTALOL (OPHTHALMIC)	0.6%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	COSOPT (OPHTHALMIC)	6.7%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	TRUSOPT (OPHTHALMIC)	1.0%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	BETIMOL (OPHTHALMIC)	1.4%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	LEVOBUNOLOL (OPHTHALMIC)	1.3%	ON	Yes-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	TRAVATAN / TRAVATAN Z 2.5 ML (OPHTHALMIC)	26.2%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	CARTEOLOL (OPHTHALMIC)	0.3%	ON	Yes-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	ALPHAGAN P (OPHTHALMIC)	9.2%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	PILOCARPINE (OPHTHALMIC)	1.3%	ON	Yes-Generic			
OPHTHALMICS,	METIPRANOLOL	0.1%	ON	Yes-Generic			

GLAUCOMA AGENTS	(OPHTHALMIC)						
OPHTHALMICS, GLAUCOMA AGENTS	BRIMONIDINE (OPHTHALMIC)	2.0%	ON	Yes-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	PROPINE (OPHTHALMIC)	0.0%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	BETAXOLOL (OPHTHALMIC)	0.2%	ON	Yes-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	AZOPT (OPHTHALMIC)	3.7%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	XALATAN 2.5 ML (OPHTHALMIC)	6.1%	OFF	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	TRAVATAN / TRAVATAN Z 5 ML (OPHTHALMIC)	5.6%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	TIMOLOL (OPHTHALMIC)	13.9%	ON	Yes-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	LUMIGAN 2.5ML (OPHTHALMIC)	10.3%	ON	No			
OPHTHALMICS, GLAUCOMA AGENTS	COMBIGAN (OPHTHALMIC)	3.8%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	BETOPTIC S (OPHTHALMIC)	1.3%	ON	Yes			
OPHTHALMICS, GLAUCOMA AGENTS	LUMIGAN 5ML (OPHTHALMIC)	3.8%	ON	No			
OPHTHALMICS, GLAUCOMA AGENTS	DORZOLAMIDE (OPHTHALMIC)	0.4%	OFF	No-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	LUMIGAN 7.5ML (OPHTHALMIC)	0.0%	OFF	No			
OPHTHALMICS, GLAUCOMA AGENTS	BRIMONIDINE P (OPHTHALMIC)	0.1%	OFF	No-Generic			
OPHTHALMICS, GLAUCOMA AGENTS	DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	0.9%	OFF	No-Generic			

- Discussion:

- Dr. Brown made a motion to accept staff recommendations as presented.
 - Second – James Boblin
 - All members were in favor of the motion.
 - Motion passes.

44. Therapeutic Drug Class	Brand Name (Route)	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications	Secretary Modifications
EPINEPHRINE, SELF-INJECTED	EPINEPHRINE (INJECTION)	0.1%	NR	No-Generic			
EPINEPHRINE, SELF-INJECTED	ADRENACLICK (INTRAMUSC)	0.1%	NR	No			
EPINEPHRINE, SELF-INJECTED	EPIPEN (INTRAMUSC)	71.0%	NR	Yes			
EPINEPHRINE, SELF-INJECTED	EPIPEN JR (INTRAMUSC)	28.4%	NR	Yes			
EPINEPHRINE,	TWINJECT	0.5%	NR	No			

SELF-INJECTED	(INTRAMUSC)						
---------------	-------------	--	--	--	--	--	--

- Discussion: New class

- Dr. Boblin made a motion to accept staff recommendations as presented.
 - Second – Ron Diamond
 - All members were in favor of the motion.
 - Motion passes.

The Committee was thanked for their time. Jason discussed the new meeting schedule put forth by Provider Synergies. The meetings will now be in May and November. The next recommended meeting dates are May 11, 2011 or May 18, 2011. We will get back to the Committee via email to set the date.